The results revealed that fall/fracture-related hospitalization and ED visit event rates in people with type 2 diabetes aged 50 years and older were numerically lower in participants who received Gla-300 vs long-acting basal insulins or NPH insulin, regardless of whether they were naive to basal insulin or switched from another basal insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.